ImageneBio Key Fundamental Indicators
| IMA Stock | 7.33 0.06 0.81% |
As of the 29th of January, ImageneBio retains the Market Risk Adjusted Performance of (0.29), standard deviation of 3.76, and Risk Adjusted Performance of (0.03). ImageneBio technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.
ImageneBio's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing ImageneBio's valuation are provided below:ImageneBio does not presently have any fundamental trends for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. ImageneBio | Build AI portfolio with ImageneBio Stock |
Is Stock space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ImageneBio. Market participants price ImageneBio higher when confident in its future expansion prospects. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive ImageneBio assessment requires weighing all these inputs, though not all factors influence outcomes equally.
ImageneBio's market price often diverges from its book value, the accounting figure shown on ImageneBio's balance sheet. Smart investors calculate ImageneBio's intrinsic value—its true economic worth—which may differ significantly from both market price and book value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Since ImageneBio's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Please note, there is a significant difference between ImageneBio's value and its price as these two are different measures arrived at by different means. Investors typically determine if ImageneBio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ImageneBio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
ImageneBio 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to ImageneBio's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of ImageneBio.
| 10/31/2025 |
| 01/29/2026 |
If you would invest 0.00 in ImageneBio on October 31, 2025 and sell it all today you would earn a total of 0.00 from holding ImageneBio or generate 0.0% return on investment in ImageneBio over 90 days. ImageneBio is related to or competes with Connect Biopharma, InflaRx NV, Kalaris Therapeutics, Shattuck Labs, Context Therapeutics, Sutro Biopharma, and Artiva Biotherapeutics. More
ImageneBio Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure ImageneBio's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess ImageneBio upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.07) | |||
| Maximum Drawdown | 16.1 | |||
| Value At Risk | (5.08) | |||
| Potential Upside | 6.76 |
ImageneBio Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for ImageneBio's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as ImageneBio's standard deviation. In reality, there are many statistical measures that can use ImageneBio historical prices to predict the future ImageneBio's volatility.| Risk Adjusted Performance | (0.03) | |||
| Jensen Alpha | (0.26) | |||
| Total Risk Alpha | (0.49) | |||
| Treynor Ratio | (0.30) |
ImageneBio January 29, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.03) | |||
| Market Risk Adjusted Performance | (0.29) | |||
| Mean Deviation | 2.6 | |||
| Coefficient Of Variation | (1,753) | |||
| Standard Deviation | 3.76 | |||
| Variance | 14.16 | |||
| Information Ratio | (0.07) | |||
| Jensen Alpha | (0.26) | |||
| Total Risk Alpha | (0.49) | |||
| Treynor Ratio | (0.30) | |||
| Maximum Drawdown | 16.1 | |||
| Value At Risk | (5.08) | |||
| Potential Upside | 6.76 | |||
| Skewness | 1.39 | |||
| Kurtosis | 2.99 |
ImageneBio Backtested Returns
ImageneBio holds Efficiency (Sharpe) Ratio of -0.057, which attests that the entity had a -0.057 % return per unit of risk over the last 3 months. ImageneBio exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check out ImageneBio's Risk Adjusted Performance of (0.03), standard deviation of 3.76, and Market Risk Adjusted Performance of (0.29) to validate the risk estimate we provide. The company retains a Market Volatility (i.e., Beta) of 0.76, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, ImageneBio's returns are expected to increase less than the market. However, during the bear market, the loss of holding ImageneBio is expected to be smaller as well. At this point, ImageneBio has a negative expected return of -0.21%. Please make sure to check out ImageneBio's potential upside, day median price, and the relationship between the treynor ratio and accumulation distribution , to decide if ImageneBio performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.77 |
Almost perfect reverse predictability
ImageneBio has almost perfect reverse predictability. Overlapping area represents the amount of predictability between ImageneBio time series from 31st of October 2025 to 15th of December 2025 and 15th of December 2025 to 29th of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of ImageneBio price movement. The serial correlation of -0.77 indicates that around 77.0% of current ImageneBio price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.77 | |
| Spearman Rank Test | -0.81 | |
| Residual Average | 0.0 | |
| Price Variance | 0.21 |
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
| Competition |
Based on the latest financial disclosure, ImageneBio has 11.18 M of shares currently outstending. This is 93.81% lower than that of the Biotechnology sector and 89.54% lower than that of the Health Care industry. The shares outstanding for all United States stocks is 98.04% higher than that of the company.
ImageneBio Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining ImageneBio's current stock value. Our valuation model uses many indicators to compare ImageneBio value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across ImageneBio competition to find correlations between indicators driving ImageneBio's intrinsic value. More Info.ImageneBio is rated third overall in operating margin category among its peers. It is rated fifth overall in current valuation category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the ImageneBio's earnings, one of the primary drivers of an investment's value.ImageneBio Shares Outstanding Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses ImageneBio's direct or indirect competition against its Shares Outstanding to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of ImageneBio could also be used in its relative valuation, which is a method of valuing ImageneBio by comparing valuation metrics of similar companies.ImageneBio is currently under evaluation in shares outstanding category among its peers.
ImageneBio Fundamentals
| Operating Margin | (5.01) % | |||
| Current Valuation | 111.51 M | |||
| Shares Outstanding | 11.18 M | |||
| Shares Owned By Insiders | 14.24 % | |||
| Shares Owned By Institutions | 33.98 % | |||
| Number Of Shares Shorted | 384.41 K | |||
| Price To Sales | 21.32 X | |||
| Revenue | 3.5 M | |||
| Gross Profit | 4.3 M | |||
| EBITDA | (35.47 M) | |||
| Net Income | (49.23 M) | |||
| Total Debt | 7.52 M | |||
| Book Value Per Share | (0.43) X | |||
| Cash Flow From Operations | (46 M) | |||
| Short Ratio | 1.31 X | |||
| Earnings Per Share | (4.33) X | |||
| Target Price | 30.0 | |||
| Market Capitalization | 91.69 M | |||
| Total Asset | 141.51 M | |||
| Retained Earnings | (331.62 M) | |||
| Working Capital | (4.74 M) | |||
| Net Asset | 141.51 M |
About ImageneBio Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze ImageneBio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ImageneBio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ImageneBio based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| VTI | Vanguard Total Stock | |
| RIOT | Riot Blockchain | |
| TSLA | Tesla Inc |
Check out For information on how to trade ImageneBio Stock refer to our How to Trade ImageneBio Stock guide.You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Is Stock space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ImageneBio. Market participants price ImageneBio higher when confident in its future expansion prospects. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive ImageneBio assessment requires weighing all these inputs, though not all factors influence outcomes equally.
ImageneBio's market price often diverges from its book value, the accounting figure shown on ImageneBio's balance sheet. Smart investors calculate ImageneBio's intrinsic value—its true economic worth—which may differ significantly from both market price and book value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Since ImageneBio's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Please note, there is a significant difference between ImageneBio's value and its price as these two are different measures arrived at by different means. Investors typically determine if ImageneBio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ImageneBio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.